Shin Nippon Biomedical Laboratories Toekomstige groei
Future criteriumcontroles 2/6
Shin Nippon Biomedical Laboratories zal naar verwachting groeien in winst en omzet met respectievelijk 5.6% en 6.7% per jaar. De winst per aandeel zal naar verwachting groeien met 5.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 14.2% zijn.
Belangrijke informatie
5.6%
Groei van de winst
5.6%
Groei van de winst per aandeel
Life Sciences winstgroei | 28.4% |
Inkomstengroei | 6.7% |
Toekomstig rendement op eigen vermogen | 14.2% |
Dekking van analisten | Low |
Laatst bijgewerkt | 31 Oct 2024 |
Recente toekomstige groei-updates
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Recent updates
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2027 | 35,370 | 6,049 | 2,610 | N/A | 2 |
3/31/2026 | 32,501 | 5,271 | -357 | N/A | 2 |
3/31/2025 | 29,140 | 3,573 | -7,409 | N/A | 2 |
6/30/2024 | 26,195 | 4,280 | N/A | N/A | N/A |
3/31/2024 | 26,450 | 5,531 | -6,498 | 2,106 | N/A |
12/31/2023 | 26,703 | 5,503 | N/A | N/A | N/A |
9/30/2023 | 26,626 | 4,607 | -4,074 | 1,899 | N/A |
6/30/2023 | 26,848 | 5,489 | N/A | N/A | N/A |
3/31/2023 | 25,090 | 6,060 | -950 | 4,004 | N/A |
12/31/2022 | 21,173 | 6,231 | N/A | N/A | N/A |
9/30/2022 | 20,135 | 8,043 | 4,382 | 7,170 | N/A |
6/30/2022 | 18,753 | 7,245 | N/A | N/A | N/A |
3/31/2022 | 17,748 | 7,127 | 4,339 | 5,952 | N/A |
12/31/2021 | 17,636 | 7,432 | N/A | N/A | N/A |
9/30/2021 | 16,068 | 6,025 | 4,075 | 5,301 | N/A |
6/30/2021 | 14,978 | 4,844 | N/A | N/A | N/A |
3/31/2021 | 15,110 | 3,661 | 3,629 | 4,746 | N/A |
12/31/2020 | 14,910 | 2,421 | N/A | N/A | N/A |
9/30/2020 | 15,175 | 2,812 | 1,389 | 2,706 | N/A |
6/30/2020 | 15,004 | 3,234 | N/A | N/A | N/A |
3/31/2020 | 14,561 | 2,550 | 1,788 | 3,018 | N/A |
12/31/2019 | 13,497 | 1,990 | N/A | N/A | N/A |
9/30/2019 | 13,167 | 1,915 | 1,784 | 2,988 | N/A |
6/30/2019 | 14,676 | 1,524 | N/A | N/A | N/A |
3/31/2019 | 15,658 | 1,950 | 1,794 | 2,892 | N/A |
12/31/2018 | 17,337 | -49 | N/A | N/A | N/A |
9/30/2018 | 17,928 | -993 | 1,631 | 2,943 | N/A |
6/30/2018 | 16,937 | -2,566 | N/A | N/A | N/A |
3/31/2018 | 16,600 | -3,555 | N/A | 1,344 | N/A |
12/31/2017 | 17,186 | -1,072 | N/A | N/A | N/A |
9/30/2017 | 17,714 | 327 | N/A | 280 | N/A |
6/30/2017 | 17,230 | 260 | N/A | N/A | N/A |
3/31/2017 | 17,244 | -915 | N/A | -849 | N/A |
12/31/2016 | 15,880 | -1,821 | N/A | N/A | N/A |
9/30/2016 | 15,269 | -1,273 | N/A | -3,109 | N/A |
6/30/2016 | 14,922 | -1,475 | N/A | N/A | N/A |
3/31/2016 | 14,750 | 2,646 | N/A | -3,339 | N/A |
12/31/2015 | 15,637 | 2,060 | N/A | N/A | N/A |
9/30/2015 | 16,344 | 401 | N/A | -2,379 | N/A |
6/30/2015 | 17,164 | 1,546 | N/A | N/A | N/A |
3/31/2015 | 17,835 | -1,385 | N/A | -2,156 | N/A |
12/31/2014 | 18,058 | -417 | N/A | N/A | N/A |
9/30/2014 | 17,161 | -599 | N/A | -1,377 | N/A |
6/30/2014 | 17,132 | -1,074 | N/A | N/A | N/A |
3/31/2014 | 16,926 | -754 | N/A | -1,620 | N/A |
12/31/2013 | 16,993 | -1,443 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei 2395 ( 5.6% per jaar) ligt boven de spaarquote ( 0.3% ).
Winst versus markt: De winst van 2395 ( 5.6% per jaar) zal naar verwachting langzamer groeien dan de markt JP ( 8.9% per jaar).
Hoge groeiwinsten: De winst van 2395 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van 2395 ( 6.7% per jaar) zal naar verwachting sneller groeien dan de markt JP ( 4.2% per jaar).
Hoge groei-inkomsten: De omzet van 2395 ( 6.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen 2395 zal naar verwachting over 3 jaar laag zijn ( 14.2 %).